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Pharmacological Treatment of Intermittent Claudication  
Does Not Have a Significant Effect on Gait Impairments 
During Claudication Pain
Jennifer M. Yentes,1 Jessie M. Huisinga,1 Sara A. Myers,1  
Iraklis I. Pipinos,2,3 Jason M. Johanning,2,3 and Nicholas Stergiou1,3
1University of Nebraska at Omaha; 2Department of Veterans’ Affairs;  
3University of Nebraska Medical Center
Peripheral arterial disease (PAD) is a manifestation of atherosclerosis resulting in intermittent claudication 
(IC) or leg pain during physical activity. Two drugs (cilostazol and pentoxifylline) are approved for treatment 
of IC. Our previous work has reported no significant differences in gait biomechanics before and after drug 
interventions when PAD patients walked without pain. However, it is possible that the drugs are more effica-
cious during gait with pain. Our aim was to use advanced biomechanical analysis to evaluate the effectiveness 
of these drugs while walking with pain. Initial and absolute claudication distances, joint kinematics, torques, 
powers, and gait velocity during the presence of pain were measured from 24 patients before and after 12 
weeks of treatment with either cilostazol or pentoxifylline. We found no significant improvements after 12 
weeks of treatment with either cilostazol or pentoxifylline on the gait biomechanics of PAD patients during 
pain. Our findings indicate that the medications cilostazol and pentoxifylline have reduced relevance in the 
care of gait dysfunction even during pain in patients with PAD.
Keywords: peripheral arterial disease, locomotion, biomechanics, cilostazol, pentoxifylline
Peripheral arterial disease (PAD) is a manifestation 
of systemic atherosclerosis, characterized by athero-
sclerotic blockages of the arteries supplying the legs, 
affecting up to 12 million elderly in the United States 
(Hirsch & Hiatt, 2001; McDermott et al., 2001; Nehler 
et al., 2003). Intermittent claudication, the most common 
manifestation of PAD, is defined as activity induced dys-
function and muscle pain (claudication pain) relieved by 
rest. When patients with intermittent claudication start 
walking, their leg muscles have adequate blood flow and 
they experience no leg pain. With continued walking, the 
metabolic needs of the exercising limb rapidly increase. 
However, the blood flow required to support these needs 
cannot be delivered due to blockages in the arterial 
system. As exercise continues, the muscles become pro-
gressively more ischemic and painful, forcing the patient 
to eventually stop walking (Regensteiner et al., 1988). 
Studies have demonstrated that patients with PAD walk 
with decreased gait velocity, cadence, step length and 
increased stance time as compared with controls (Gardner 
et al., 2001). Recently, biomechanical investigations have 
revealed that PAD patients demonstrate abnormal ground 
reaction forces and altered joint kinetics and kinematics, 
before and after the onset of claudication pain as com-
pared with healthy controls (Celis et al., 2009; Chen et 
al., 2008; Crowther et al., 2007; Koutakis et al., 2010a; 
Scott-Pandorf et al., 2007).
Treatments for PAD range from risk factor man-
agement (e.g., exercise, smoking cessation) to more 
aggressive surgical interventions (e.g., surgical bypass 
and endovascular revascularization; Antignani, 2003; 
Aronow, 2007; Christman et al., 2001; Schainfeld, 2001). 
Currently, two pharmacological agents are approved by 
the United States Food and Drug Administration for treat-
ment of PAD. The first approved drug, pentoxifylline, a 
xanthine derivative, acts as a competitive nonselective 
phosphodiesterase inhibitor (PMID 11692087) and 
a nonselective adenosine receptor antagonist (PMID 
3588607). The second approved medication, cilostazol, 
is a phosphodiesterase inhibitor that has antiplatelet and 
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vasodilatory effects (Lipsitz & Kim, 2008; Regensteiner 
& Stewart, 2006). The objective for the use of the two 
medications is to improve the walking function of patients 
with claudication by improving blood flow at all times. 
In most studies evaluating effects of medications on clau-
dication, walking function has been evaluated with the 
measurement of the initial claudication distance (distance 
walked before the onset of claudication symptoms) and 
of the absolute claudication distance (maximal distance 
the patient can walk). Certain studies have demonstrated 
improved walking distances with pentoxifylline (Accetto, 
1982; Cesarone et al., 2002; De Sanctis et al., 2002; 
Dettori et al., 1989; Di Perri et al., 1984; Perhoniemi et 
al., 1984) and cilostazol treatment (Beebe et al., 1999; 
Dawson et al., 1998; Robless et al., 2008; Thompson 
et al., 2002). Conversely, studies have also found no 
changes in walking distances with either pentoxifylline 
(Reilly et al., 1987) or cilostazol (O’Donnell et al., 2009). 
Moreover, in a trial comparing the two medications to 
each other and to placebo, cilostazol shows significant 
improvements in absolute claudication distance and 
initial claudication distance while no significant differ-
ences were found between the pentoxifylline and placebo 
groups (Dawson et al., 2000).
Due to conflicting results found regarding both 
pharmacological treatments, there is a need for more 
sensitive measures to quantify the functional outcomes 
of these pharmacological interventions. Using advanced 
biomechanical analysis, investigators have been able to 
characterize gait abnormalities in several pathologies 
(Barker et al., 2006; Basford et al., 2003; Chang et al., 
2006; Tenore et al., 2006). Specifically, joint moments 
can determine the net response of all muscle groups in 
the lower extremities and the crucial PAD-related adapta-
tions and deficits in muscle function during gait (Winter, 
2005). Joint powers can then determine the contribution 
of the torque-producing muscle groups to the funda-
mental biomechanical processes of energy generation 
and energy dissipation through concentric and eccentric 
contractions of skeletal muscles (Winter, 2005). Our 
laboratory has used this approach to define baseline gait 
deficit in PAD patients (Celis et al., 2009; Koutakis et 
al., 2010a). Furthermore, we recently investigated the 
effect of therapy with pentoxifylline and cilostazol on 
biomechanical gait parameters in PAD patients walking 
before the onset of claudication pain (Huisinga et al., 
2010a, 2010b). Specifically, Huisinga et al. (Huisinga 
et al., 2010a) compared patients with PAD that were 
treated with either one of the pharmacological agents with 
healthy controls. Patients were not grouped separately by 
pharmacological treatment (i.e., were compared as one 
group to the controls) and they were tested only under 
a pain free condition. Therefore, this research design 
did not explore the separate effects of the two agents. 
Thus, in a follow-up study Huisinga et al. (Huisinga et 
al., 2010b) separated patients with PAD into two groups 
that were exposed to the two agents. Then, the authors 
compared the two groups under a pain free condition. Col-
lectively, these two studies showed that post 3 months of 
treatment no identifiable biomechanical alterations were 
produced as compared with the aged-matched controls 
(Huisinga et al., 2010a). Further, when patients with 
PAD were separated to two groups based on treatment, 
no significant differences were found between the two 
groups for either treatment (before vs. after 12 weeks of 
therapy) for gait velocity, absolute claudication distance, 
joint kinematic and peak joint torque values (Huisinga et 
al., 2010b). These results indicate that three months of 
pharmacological therapy did not have an effect on joint 
kinematic or kinetic parameters of PAD patients while 
they are walking before they experience claudication 
pain. These findings also suggest that for improvements 
in functional outcomes of patients walking before the 
onset of claudication pain, physicians cannot rely solely 
on pharmacological interventions.
On the other hand, it may be possible that pharma-
cological treatment produces appreciable effects in the 
biomechanics of patients mainly while they are walking 
with claudication pain, when blood flow is restricted 
and limbs suffer from ischemia. These pharmacological 
treatments are even marketed as being able to improve 
pain in PAD patients. Further, it is known that walking 
with claudication pain does significantly impact biome-
chanical gait parameters, with the ankle musculature 
demonstrating the greatest deficits (Koutakis et al., 
2010b). As stated before, patients with PAD experi-
ence a cycle of ischemia and reperfusion. It is possible 
that the effects of pentoxifylline and cilostazol may 
help to improve blood flow specifically during activity 
and potentially attenuate the patient’s ischemic state. As 
the metabolic demand increases with exertion, the two 
medications may be able to support aerobic metabolism 
with an increased supply of oxygen and glucose (Carman 
& Fernandez, 2006).
Therefore, the purpose of the current study was to 
investigate the effects of pharmacological treatments on 
the biomechanics of gait of PAD patients while experienc-
ing claudication pain. Joint kinetic and kinematic param-
eters were used to evaluate gait impairments after the 
onset of claudication pain. This evaluation was performed 
before pharmacological treatment and 12 weeks after the 
commencement of treatment. We hypothesize that treat-
ment with the medications will have a positive effect on 
patients’ gait parameters post treatment. The drugs have 
been designed to increase blood flow upon exertion and 
even during continued walking and sustained metabolic 
demand. Therefore, improvements could be noted as we 
know decrements in gait during walking with pain are 
present (Koutakis et al., 2010b). If improvements are 
demonstrated, then there would be reason to believe that 
improved gait mechanics would eventually lead over time 
to improved maximal walking distances, thus, warranting 
use of these drugs. However, if no improvements in gait 
mechanics and/or walking distances can be found, then 
prescription of such pharmacological agents may not be 
warranted. In addition, it is expected that cilostazol will 
have more of an impact than pentoxifylline. This is due 
to findings in which cilostazol demonstrated significant 
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increase in walking distances as compared with pentoxi-
fylline (Dawson et al., 2000).
Methods
Subject Inclusion and Exclusion Criteria
Patients presenting with intermittent claudication of at 
least one lower limb and intended to undergo pharma-
cological treatment were recruited from the vascular 
surgery clinics of the University of Nebraska and the 
Western Iowa–Nebraska Veterans’ Affairs Medical 
Centers. The institutional review boards of the two 
institutions approved all procedures. All participants 
provided informed consent before enrollment into the 
study. A total of 24 PAD patients were enrolled (67.8 
± 9.6 years); 14 participants were prescribed cilostazol 
and 10 participants were prescribed pentoxifylline. Drug 
assignment was nonrandomized, nonblinded, and based 
upon each patient’s past medical history and current 
medication profile.
Patients were specifically evaluated by two board-
certified vascular surgeons before enrollment in the 
study to ensure that walking impairments were second-
ary to claudication pain. Patients were excluded if they 
demonstrated ambulation limiting cardiac, pulmonary, 
neuromuscular, or musculoskeletal disease or those who 
experienced pain or discomfort during walking for rea-
sons other than claudication. Patient evaluation included 
resting ankle brachial index (ABI; a measurement below 
0.90 defined PAD), detailed history, and physical exam. 
Affected limbs were identified if the ABI was less than 
0.9 and expressed symptoms of intermittent claudication.
Experimental Procedures  
and Data Collection
Reflective markers were placed on anatomical locations, 
bilaterally, according to a modified Helen Hayes marker 
set (Houck et al., 2005). To induce claudication pain, 
subjects were asked to walk on a treadmill at 0.67 m/s at 
a 10% incline until the presentation of claudication symp-
toms (DiBianco et al., 1984). The constant work load 
protocol has been shown to be reliable in inducing clau-
dication pain (Labs et al., 1999). Claudication symptoms 
were self-reported by the patient. Before the treadmill 
protocol, subjects were asked what their normal claudi-
cation symptoms were like, pain and/or cramping in the 
buttock, thigh, and/or leg. Research staff asked specific 
questions regarding claudication pain once every minute 
until patients reported claudication symptoms similar to 
what they would experience in daily life. For instance, 
patients would be asked, “Are you having any pain or 
cramping in your legs?” and once the patient reported yes, 
the research staff would inquire as to where the pain was 
and what type. The onset of claudication symptoms was 
defined, when the patient reported that they felt it was 
similar to their daily claudication symptoms or asked to 
stop. Once the onset of claudication symptoms was felt 
by the subject, they were immediately removed from the 
treadmill and walked through a 10 m walkway. Five trials 
were collected for each affected limb; 10 trials total if 
they presented with bilateral PAD. Participants were not 
allowed to rest during the data collection to provide for 
experimental data to be collected while the patient was 
experiencing claudication pain. The 3D marker trajecto-
ries were collected with a digital high-speed eight-camera 
system (EvaRT 5.0.4, Motion Analysis Corp., Santa 
Rosa, CA) sampling at 60 Hz. Ground reaction force 
data from heel contact to toe-off was collected using 
a piezoelectric force plate (Kistler Instrument Corp., 
Winterthur, Switzerland) sampling at 600 Hz. To ensure 
that a complete stance phase would be collected during 
each overground walking trial during claudication pain, 
starting positions for each limb were determined before 
having the subject walk on the treadmill to induce pain. 
It has been shown that step lengths do not change from 
the pain-free to pain condition and thus patients would 
maintain similar spatial gait patterns between the two 
conditions (Koutakis et al., 2010b).
Initial claudication distance and absolute claudica-
tion distance were measured at the end of the data collec-
tion session. Patients were required to rest for a minimum 
of 5 min and until all claudication pain had subsided 
after all overground walking trials were collected. Once 
patients were pain free, they were asked to walk on the 
treadmill at a speed of 0.67 m/s at a 10% incline until 
they were unable to continue due to claudication pain 
(DiBianco et al., 1984). Initial claudication distances 
were based upon the patient’s first report of claudication 
pain. Absolute claudication distances were based on the 
patient’s self-reported maximum tolerable pain.
Data collection was completed before the admin-
istration of pharmacological treatments and again at 12 
weeks after treatment commenced. This time frame is 
appropriate since 12 weeks is the minimum amount of 
time allotted before declaring a patient as unresponsive 
to a medication (Carman & Fernandez, 2006). During 
the treatment period, patients were not restricted from 
performing extra training and their physical activity levels 
were not monitored. Gait kinematics and kinetics were 
calculated from the sagittal plane of motion during the 
stance phase of walking for each subject after intermit-
tent claudication was exhibited in the affected limb(s). 
No swing phase data were analyzed. A low-pass, fourth-
order Butterworth filter with a 7 Hz cutoff was used to 
smooth the marker trajectories before data processing. 
Custom MatLab programs (MatLab 2007, Mathworks, 
Inc., Concord, MA) were used for calculation of all 
dependent variables. Using the methods described by 
Vaughn et al. (1992) and Nigg et al. (1993), relative 
joint angles were calculated. Joint range of motion was 
defined as the maximum range of the joint angle during 
the stance phase of walking. Inverse dynamics were used 
to calculate joint torques of each joint and were scaled to 
body weight and height (Winter, 2005). Extensor torques 
were represented by positive torque values while negative 
torque values represent flexor torques. Joint powers were 
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calculated as the product of the net joint torque and angu-
lar velocity. Positive joint power values indicate power 
generation while a negative joint power values indicate 
power absorption. Peak torques and peak powers were 
recorded for the hip, knee, and ankle.
Group means of each dependent variable was cal-
culated for the therapy (before and after) group and for 
the treatment group (cilostazol and pentoxifylline) by 
combining all legs of each group. Out of the 14 partici-
pants given cilostazol, 26 limbs were evaluated because 
two patients had unilateral claudication only and of the 
10 participants given pentoxifylline, all 20 limbs were 
evaluated. All dependent variables were tested for normal-
ity using the Shapiro-Wilk procedure. There was a strong 
tendency for normality and thus a repeated-measures 2 × 
2 ANOVA was performed for the within (before vs. after) 
and the between (cilostazol vs. pentoxifylline) factors 
using SPSS software (SPSS 16.0, SPSS, Inc., Chicago, 
IL). Due to a large number of comparisons, a Bonferroni 
correction was employed. Mean difference was calculated 
for each dependent variable using effect size, which is the 
mean of the pre-therapy minus the mean of post-therapy 
divided by the standard deviation of the pre-therapy. The 
significance level was set at p < .0025 (0.05 divided by 
20 (20 dependent variables presented in Table 1)).
Results
No significant main effects were found due to therapy 
or treatment group for gait velocity, initial claudication 
distance, absolute claudication distance, joint range of 
motions, joint torque parameters, or joint powers (Table 
1). In addition, no significant interactions were found 
between therapy and treatment group for these variables. 
Importantly, if a less conservative p-value was adopted 
(p < 0.05), only 6 out of the total 60 F-ratios would have 
been significant (Table 1). Due to therapy there were only 
2 out of 60 F-ratios that were significant. These two were 
the variables of knee power absorption in early stance 
and hip power generation in late stance (Table 1). Due 
to treatment group there were again 2 out of 60 F-ratios 
that were significant. These two were the variables of 
gait velocity and ankle power generation in late stance 
(Table 1). The two variables that were significant due 
to therapy were not the same for the treatment, further 
strengthening this point.
Discussion
The purpose of this study was to investigate the effect 
of pharmacological treatment on the gait abnormalities 
exhibited by PAD patients while they walk with claudica-
tion pain. It was hypothesized that a 12-week course of 
pharmacological treatment would have a positive effect 
on patients’ gait parameters post treatment. Further, it was 
expected that cilostazol would attenuate gait parameters 
more so than pentoxifylline. The current findings refute 
these hypotheses as we now accept the null hypothesis.
These data presented in this study demonstrate that 
neither treatment group (pentoxifylline vs. cilostazol) 
nor therapy (before vs. after) had a significant effect on 
gait impairment in patients with PAD. Due to the large 
number of dependent variables evaluated in this study, 
a more stringent p-value (p < 0.0025) was employed to 
accommodate for the number of comparisons performed 
(Table 1). Interestingly, if a less stringent p-value (p < 
0.05) would have been used, only 6 of 60 F-ratios cal-
culated would have reached significance (Table 1). The 
lack of significant changes in gait parameters indicates 
that 12 weeks of treatment with cilostazol or pentoxifyl-
line produce no appreciable improvements in the gait 
biomechanics of claudicating patients. In addition, our 
measurements of walking distances demonstrate changes 
in absolute claudication distance in the cilostazol group 
(improvement) and in the pentoxifylline group (decre-
ment) but neither of the two changes reached statistical 
significance. Our findings from advanced biomechanical 
analysis of PAD gait are further supported by studies in 
which it has been found that these medications do not 
improve claudication distances (O’Donnell et al., 2009; 
Reilly et al., 1987). Reilly et al. (1987) have stated that 
pentoxifylline has limited effect on blood flow proper-
ties and no effect on claudication distances. Further, 
O’Donnell et al. (O’Donnell et al., 2009) have shown that 
despite improvements in quality of life after 24 weeks 
of cilostazol treatment, no significant differences were 
demonstrated in walking distances. Taken together, the 
findings from the current study and those reported by 
Huisinga et al. (2010a, 2010b) suggest that the medica-
tions cilostazol and pentoxifylline have limited applica-
tion in the clinical treatment of the gait dysfunction of 
patients with peripheral arterial disease regardless of the 
presence of claudication pain.
It is logical to conclude that based on the findings in 
the current study, cilostazol and pentoxifylline are unable 
to provide a sufficient change in the dynamics of the neu-
romuscular system of the lower extremities to improve 
functional outcomes during claudication pain. Myopathy 
and neuropathy (PMID 18390972 and PMID 18166628) 
that is present in patients with peripheral arterial disease 
is a key factor to the pathogenesis of this disease (Pipinos 
et al., 2007). It has been shown that skeletal muscle tissue 
in patients with PAD is vastly different than healthy con-
trols. PAD patients suffer from various levels of oxidative 
stress resulting in mitochondrial abnormalities (Pipinos 
et al., 2003, 2006), besides shifts in muscle fiber types 
(Regensteiner et al., 1993), and neuropathy (Pasini et al., 
1996; Weber & Ziegler, 2002). This myopathy is possibly 
related to function, for instance, muscle weakness due to 
inability to produce energy as a result of mitochondrial 
changes. Future therapeutic approaches focusing on the 
neuro-myopathy of PAD may produce improved gait and 
reduced impairment associated with the disease.
These data presented in study are in line with previ-
ous findings within patients with PAD. Normative data 
for the range of motion for the three joints are typically 
approximately 40, 18 and 18 degrees for the hip, knee 
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and ankle respectively during the stance phase of walking 
(Celis et al., 2009). Our findings are also consistent with 
other studies that found decreased range of motion at the 
hip and knee with increased range of motion at the ankle 
in patients with PAD as compared with controls (Celis 
et al., 2009; Huisinga et al., 2010a). In addition, joint 
torque and power values were compared with published 
literature in which similarly aged healthy controls were 
reported (Koutakis et al., 2010b). The data from this study 
demonstrate that all joint torque and power magnitudes 
(absolute value) reported were decreased as compared 
with controls, with the exception of peak knee flexor 
torque. This is also consistent with previous findings for 
patients with PAD (Huisinga et al., 2010a; Koutakis et 
al., 2010b). Our data are similar to published values that 
have been normalized to body weight (Eng & Winter, 
1995; Nadeau et al., 2003).
Overall, our data demonstrate that a 12-week treat-
ment of PAD with either cilostazol or pentoxifylline does 
not result in biomechanical changes in the gait biome-
chanics of claudicating patients. The lack of changes in 
gait improvement suggests that underlying myopathy 
and neuropathy may limit the ability of the medications 
to produce improvements in gait biomechanics; conse-
quently, reducing the relevance of the use of these two 
medications in the clinical care of gait dysfunction in 
peripheral arterial disease. Future studies should focus 
on evaluating surgical revascularization and supervised 
exercise as therapies with established and more marked 
positive effects in the walking ability of PAD patients. The 
use of advanced biomechanical analysis in such studies 
would allow identification of the particular joint muscular 
responses and contributions that lead to improvement in 
the ambulation of patients with claudication.
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